Angiotensin-converting enzyme inhibitor usage and acute kidney injury: A secondary analysis of RENAL study outcomes

RENAL STUDY INVESTIGATORS, ANZICS CLINICAL TRIALS GROUP

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Aim: Acute kidney injury (AKI) is associated with increased mortality. While angiotensin-converting enzyme inhibitors (ACEI) are known to slow progression of chronic kidney disease, their role in AKI remains unclear. Methods: The Randomised Evaluation of Normal vs. Augmented Level Replacement Therapy (RENAL) study data were analysed according to ACEI use over time. The primary outcome was all-cause mortality at 90 days following randomisation. Analyses used a multivariate Cox model adjusted for either baseline or for time-dependent covariates, and a sensitivity analysis of patients surviving to at least the median time to ACEI initiation. Results: Of the 1463 participants with available data on ACE inhibitors usage, 142 (9.7%) received ACEI at least once during study data collection. Participants treated with ACEI were older (P = 0.02) and had less sepsis at baseline (P < 0.001). ACEI use was significantly associated with lower mortality at 90 days (HR 0.46, 95% CI 0.30-0.71, P < 0.001), and an increase in renal replacement therapy-free days (P < 0.001), intensive care unit-free days (P < 0.001) and hospital free-days (P < 0.001) after adjusting for baseline covariates. Using the time-dependent analysis, however, the effect of ACEI administration was not significant (HR 0.78, 95% CI 0.51-1.21, P = 0.3). The sensitivity analysis in day 8 survivors produced similar results. Conclusion: In the RENAL study cohort, the use of ACEI during the study was not common and, after adjustment for time-dependent covariates, was not significantly associated with reductions in mortality. Further assessment of the effect of ACEI use in AKI patients is needed.

Original languageEnglish
Pages (from-to)617-622
Number of pages6
JournalNephrology
Volume19
Issue number10
DOIs
Publication statusPublished - Oct 1 2014

Fingerprint

Angiotensin-Converting Enzyme Inhibitors
Acute Kidney Injury
Outcome Assessment (Health Care)
Mortality
Renal Replacement Therapy
Random Allocation
Chronic Renal Insufficiency
Proportional Hazards Models
Intensive Care Units
Survivors
Sepsis
Cohort Studies

All Science Journal Classification (ASJC) codes

  • Nephrology

Cite this

Angiotensin-converting enzyme inhibitor usage and acute kidney injury : A secondary analysis of RENAL study outcomes. / RENAL STUDY INVESTIGATORS; ANZICS CLINICAL TRIALS GROUP.

In: Nephrology, Vol. 19, No. 10, 01.10.2014, p. 617-622.

Research output: Contribution to journalArticle

RENAL STUDY INVESTIGATORS ; ANZICS CLINICAL TRIALS GROUP. / Angiotensin-converting enzyme inhibitor usage and acute kidney injury : A secondary analysis of RENAL study outcomes. In: Nephrology. 2014 ; Vol. 19, No. 10. pp. 617-622.
@article{e97afd98c7204afbba562de063d0b7c4,
title = "Angiotensin-converting enzyme inhibitor usage and acute kidney injury: A secondary analysis of RENAL study outcomes",
abstract = "Aim: Acute kidney injury (AKI) is associated with increased mortality. While angiotensin-converting enzyme inhibitors (ACEI) are known to slow progression of chronic kidney disease, their role in AKI remains unclear. Methods: The Randomised Evaluation of Normal vs. Augmented Level Replacement Therapy (RENAL) study data were analysed according to ACEI use over time. The primary outcome was all-cause mortality at 90 days following randomisation. Analyses used a multivariate Cox model adjusted for either baseline or for time-dependent covariates, and a sensitivity analysis of patients surviving to at least the median time to ACEI initiation. Results: Of the 1463 participants with available data on ACE inhibitors usage, 142 (9.7{\%}) received ACEI at least once during study data collection. Participants treated with ACEI were older (P = 0.02) and had less sepsis at baseline (P < 0.001). ACEI use was significantly associated with lower mortality at 90 days (HR 0.46, 95{\%} CI 0.30-0.71, P < 0.001), and an increase in renal replacement therapy-free days (P < 0.001), intensive care unit-free days (P < 0.001) and hospital free-days (P < 0.001) after adjusting for baseline covariates. Using the time-dependent analysis, however, the effect of ACEI administration was not significant (HR 0.78, 95{\%} CI 0.51-1.21, P = 0.3). The sensitivity analysis in day 8 survivors produced similar results. Conclusion: In the RENAL study cohort, the use of ACEI during the study was not common and, after adjustment for time-dependent covariates, was not significantly associated with reductions in mortality. Further assessment of the effect of ACEI use in AKI patients is needed.",
author = "{RENAL STUDY INVESTIGATORS} and {ANZICS CLINICAL TRIALS GROUP} and Wang, {Amanda Y.} and Rinaldo Bellomo and Toshiharu Ninomiya and Serigne Lo and Alan Cass and Meg Jardine and Martin Gallagher",
year = "2014",
month = "10",
day = "1",
doi = "10.1111/nep.12284",
language = "English",
volume = "19",
pages = "617--622",
journal = "Nephrology",
issn = "1320-5358",
publisher = "Wiley-Blackwell",
number = "10",

}

TY - JOUR

T1 - Angiotensin-converting enzyme inhibitor usage and acute kidney injury

T2 - A secondary analysis of RENAL study outcomes

AU - RENAL STUDY INVESTIGATORS

AU - ANZICS CLINICAL TRIALS GROUP

AU - Wang, Amanda Y.

AU - Bellomo, Rinaldo

AU - Ninomiya, Toshiharu

AU - Lo, Serigne

AU - Cass, Alan

AU - Jardine, Meg

AU - Gallagher, Martin

PY - 2014/10/1

Y1 - 2014/10/1

N2 - Aim: Acute kidney injury (AKI) is associated with increased mortality. While angiotensin-converting enzyme inhibitors (ACEI) are known to slow progression of chronic kidney disease, their role in AKI remains unclear. Methods: The Randomised Evaluation of Normal vs. Augmented Level Replacement Therapy (RENAL) study data were analysed according to ACEI use over time. The primary outcome was all-cause mortality at 90 days following randomisation. Analyses used a multivariate Cox model adjusted for either baseline or for time-dependent covariates, and a sensitivity analysis of patients surviving to at least the median time to ACEI initiation. Results: Of the 1463 participants with available data on ACE inhibitors usage, 142 (9.7%) received ACEI at least once during study data collection. Participants treated with ACEI were older (P = 0.02) and had less sepsis at baseline (P < 0.001). ACEI use was significantly associated with lower mortality at 90 days (HR 0.46, 95% CI 0.30-0.71, P < 0.001), and an increase in renal replacement therapy-free days (P < 0.001), intensive care unit-free days (P < 0.001) and hospital free-days (P < 0.001) after adjusting for baseline covariates. Using the time-dependent analysis, however, the effect of ACEI administration was not significant (HR 0.78, 95% CI 0.51-1.21, P = 0.3). The sensitivity analysis in day 8 survivors produced similar results. Conclusion: In the RENAL study cohort, the use of ACEI during the study was not common and, after adjustment for time-dependent covariates, was not significantly associated with reductions in mortality. Further assessment of the effect of ACEI use in AKI patients is needed.

AB - Aim: Acute kidney injury (AKI) is associated with increased mortality. While angiotensin-converting enzyme inhibitors (ACEI) are known to slow progression of chronic kidney disease, their role in AKI remains unclear. Methods: The Randomised Evaluation of Normal vs. Augmented Level Replacement Therapy (RENAL) study data were analysed according to ACEI use over time. The primary outcome was all-cause mortality at 90 days following randomisation. Analyses used a multivariate Cox model adjusted for either baseline or for time-dependent covariates, and a sensitivity analysis of patients surviving to at least the median time to ACEI initiation. Results: Of the 1463 participants with available data on ACE inhibitors usage, 142 (9.7%) received ACEI at least once during study data collection. Participants treated with ACEI were older (P = 0.02) and had less sepsis at baseline (P < 0.001). ACEI use was significantly associated with lower mortality at 90 days (HR 0.46, 95% CI 0.30-0.71, P < 0.001), and an increase in renal replacement therapy-free days (P < 0.001), intensive care unit-free days (P < 0.001) and hospital free-days (P < 0.001) after adjusting for baseline covariates. Using the time-dependent analysis, however, the effect of ACEI administration was not significant (HR 0.78, 95% CI 0.51-1.21, P = 0.3). The sensitivity analysis in day 8 survivors produced similar results. Conclusion: In the RENAL study cohort, the use of ACEI during the study was not common and, after adjustment for time-dependent covariates, was not significantly associated with reductions in mortality. Further assessment of the effect of ACEI use in AKI patients is needed.

UR - http://www.scopus.com/inward/record.url?scp=84907857679&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84907857679&partnerID=8YFLogxK

U2 - 10.1111/nep.12284

DO - 10.1111/nep.12284

M3 - Article

C2 - 24894685

AN - SCOPUS:84907857679

VL - 19

SP - 617

EP - 622

JO - Nephrology

JF - Nephrology

SN - 1320-5358

IS - 10

ER -